Literature DB >> 16148487

The use of dexmedetomidine to facilitate acute discontinuation of opioids after cardiac transplantation in children.

Julia C Finkel1, Yewande J Johnson, Zenaide M N Quezado.   

Abstract

OBJECTIVE: To report the use of dexmedetomidine to facilitate rapid opioid and benzodiazepine withdrawal in children with transplanted hearts and to review the receptor physiology and pharmacodynamic impact of dexmedetomidine on the denervated heart.
DESIGN: Case series.
SETTING: Intensive care unit at a tertiary pediatric medical center. PATIENTS: The series included a 6-month-old infant with pulmonary atresia who had a 3-month exposure to high-dose opioids and benzodiazepines and had undergone cardiac transplantation 4 wks before the use of dexmedetomidine and a 7-yr-old boy who had been sedated while undergoing extracorporeal membrane oxygenation for 3 wks before transplantation and started to receive dexmedetomidine 3 days after transplantation. INTERVENTION: Administration of dexmedetomidine to facilitate the discontinuation of opioids and benzodiazepine. MAIN RESULT: Successful rapid withdrawal from opioids and benzodiazepines while maintaining hemodynamic stability.
CONCLUSION: To our knowledge, this report describes the first use of dexmedetomidine to facilitate opioid withdrawal in children with a cardiac transplant. Dexmedetomidine allowed for the preservation of satisfactory hemodynamic parameters during acute withdrawal from opioids in children with denervated hearts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16148487     DOI: 10.1097/01.ccm.0000178183.21883.23

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  13 in total

1.  Neurologic withdrawal symptoms following abrupt discontinuation of a prolonged dexmedetomidine infusion in a child.

Authors:  Jamie L Miller; Christine Allen; Peter N Johnson
Journal:  J Pediatr Pharmacol Ther       Date:  2010-01

Review 2.  Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes?

Authors:  Timothy E Albertson; James Chenoweth; Jonathan Ford; Kelly Owen; Mark E Sutter
Journal:  J Med Toxicol       Date:  2014-12

Review 3.  Dexmedetomidine: applications for the pediatric patient with congenital heart disease.

Authors:  Joseph D Tobias; Punkaj Gupta; Aymen Naguib; Andrew R Yates
Journal:  Pediatr Cardiol       Date:  2011-09-10       Impact factor: 1.655

4.  Dexmedetomidine as an Adjuvant to Analgesic Strategy During Vaso-Occlusive Episodes in Adolescents with Sickle-Cell Disease.

Authors:  Kathy A Sheehy; Julia C Finkel; Deepika S Darbari; Michael F Guerrera; Zenaide M N Quezado
Journal:  Pain Pract       Date:  2015-07-23       Impact factor: 3.183

Review 5.  Clinical uses of dexmedetomidine in pediatric patients.

Authors:  Hanna Phan; Milap C Nahata
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

6.  Dexmedetomidine Use in Critically Ill Children With Acute Respiratory Failure.

Authors:  Mary Jo C Grant; James B Schneider; Lisa A Asaro; Brenda L Dodson; Brent A Hall; Shari L Simone; Allison S Cowl; Michele M Munkwitz; David Wypij; Martha A Q Curley
Journal:  Pediatr Crit Care Med       Date:  2016-12       Impact factor: 3.624

Review 7.  Dexmedetomidine: a review of applications for cardiac surgery during perioperative period.

Authors:  Xiaoyu Zhang; Xuan Zhao; Yingwei Wang
Journal:  J Anesth       Date:  2014-06-10       Impact factor: 2.078

Review 8.  Tolerance and withdrawal from prolonged opioid use in critically ill children.

Authors:  Kanwaljeet J S Anand; Douglas F Willson; John Berger; Rick Harrison; Kathleen L Meert; Jerry Zimmerman; Joseph Carcillo; Christopher J L Newth; Parthak Prodhan; J Michael Dean; Carol Nicholson
Journal:  Pediatrics       Date:  2010-04-19       Impact factor: 7.124

9.  Analysis of benzodiazepine withdrawal program managed by primary care nurses in Spain.

Authors:  Cristina Lopez-Peig; Xavier Mundet; Bartomeu Casabella; Jose Luis del Val; David Lacasta; Eduard Diogene
Journal:  BMC Res Notes       Date:  2012-12-13

10.  Characterization of spinal alpha-adrenergic modulation of nociceptive transmission and hyperalgesia throughout postnatal development in rats.

Authors:  S M Walker; M Fitzgerald
Journal:  Br J Pharmacol       Date:  2007-05-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.